Related Experiment Video

Updated: Aug 7, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

Cilostazol inhibits vascular smooth muscle cell growth by downregulation of the transcription factor E2F

Mi-Jung Kim1, Keun-Gyu Park, Kyeong-Min Lee

  • 1Department of Internal Medicine, Keimyung University School of Medicine, Daegu, South Korea.

Hypertension (Dallas, Tex. : 1979)
|February 23, 2005
PubMed

Insights

Cilostazol inhibits vascular smooth muscle cell proliferation and neointimal formation, particularly in diabetic patients. This effect is linked to the suppression of the E2F transcription factor and its related cell cycle genes.

Area of Science:

  • Cardiovascular Biology
  • Molecular Medicine
  • Pharmacology

Background:

  • Neointimal formation, driven by vascular smooth muscle cell (VSMC) proliferation, is a primary cause of restenosis.
  • Diabetic patients exhibit increased restenosis rates post-coronary angioplasty.
  • Cilostazol, a phosphodiesterase 3 inhibitor, treats diabetic vascular complications and inhibits VSMC proliferation.

Purpose of the Study:

  • To investigate if cilostazol's antiproliferative effect on VSMCs is mediated by inhibiting the E2F transcription factor.
  • To explore cilostazol's impact on high-glucose-induced VSMC proliferation and neointimal formation.

Main Methods:

  • In vitro studies using human VSMCs exposed to high glucose.
  • In vivo studies involving rat carotid artery injury models.
  • Analysis of E2F-DNA binding activity and protein expression (E2F1, E2F2, cyclin A, PCNA).

Main Results:

  • Cilostazol inhibited human VSMC proliferation under high-glucose conditions.
  • Cilostazol significantly reduced neointimal formation in a rat carotid artery injury model.
  • The compound suppressed high-glucose-induced E2F-DNA binding and decreased E2F1, E2F2, cyclin A, and PCNA protein levels.

Conclusions:

  • Cilostazol's beneficial effects on high-glucose-stimulated VSMC proliferation are mediated by downregulating E2F activity.
  • This downregulation affects the expression of key cell cycle genes (E2F1, E2F2, cyclin A, PCNA).
  • Cilostazol shows promise in mitigating restenosis, especially in diabetic patients.

More Related Videos

Murine Aortic Crush Injury: An Efficient In Vivo Model of Smooth Muscle Cell Proliferation and Endothelial Function06:14

Murine Aortic Crush Injury: An Efficient In Vivo Model of Smooth Muscle Cell Proliferation and Endothelial Function

Published on: June 11, 2017

Isolation of Primary Patient-specific Aortic Smooth Muscle Cells and Semiquantitative Real-time Contraction Measurements In Vitro08:28

Isolation of Primary Patient-specific Aortic Smooth Muscle Cells and Semiquantitative Real-time Contraction Measurements In Vitro

Published on: February 15, 2022

Related Concept Videos

Cell Specific Gene Expression01:58

Cell Specific Gene Expression

Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...